Neurofibromatosis 2011: a report of the Children’s Tumor Foundation Annual Meeting

Michel Kalamarides, Maria T. Acosta, Dusica Babovic-Vuksanovic, Olli Carpen, Karen Cichowski, D. Gareth Evans, Filippo Giancotti, C. Oliver Hanemann, David Ingram, Alison C. Lloyd, Debra A. Mayes, Ludwine Messiaen, Helen Morrison, Kathryn North, Roger Packer, Duojia Pan, Anat Stemmer-Rachamimov, Meena Upadhyaya, David Viskochil, Margret R. Wallace, Kim Hunter-Schaedle, Nancy Ratner

The 2011 annual meeting of the Children's Tumor Foundation, the annual gathering of the neurofibromatosis (NF) research and clinical communities, was attended by 330 participants who discussed integration of new signaling pathways into NF research, the appreciation for NF mutations in sporadic cancers, and an expanding pre-clinical and clinical agenda. NF1, NF2, and schwannomatosis collectively affect approximately 100,000 persons in US, and result from mutations in different genes. Benign tumors of NF1 (neurofibroma and optic pathway glioma) and NF2 (schwannoma, ependymoma, and meningioma) and schwannomatosis (schwannoma) can cause significant morbidity, and there are no proven drug treatments for any form of NF. Each disorder is associated with additional manifestations causing morbidity. The research presentations described in this review covered basic science, preclinical testing, and results from clinical trials, and demonstrate the remarkable strides being taken toward understanding of and progress toward treatments for these disorders based on the close interaction among scientists and clinicians.